Exact Sciences risk/reward positive, says Canaccord Canaccord said the scenario analysis of upcoming catalysts suggests positive risk/reward for the shares of Exact Sciences. The firm cited its potential for reimbursement approvals form both the CMS and commercial payers. Shares of Exact Sciences remain Buy rated with a $21 price target.
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.